Between January and July 2024, 20 evaluable patients (nine with type I and 11 with type II LMD) were accrued and received HER3-DXd 5.6 mg kg−1 intravenously every 3 weeks. Here, ERBB3 is linked to Langer mesomelic dysplasia.